Andrew de Guttadauro
About Andrew de Guttadauro
Andrew de Guttadauro is a seasoned Chief Business Officer with extensive experience in biopharma business development and commercialization, known for securing significant partnerships and funding for pharmaceutical studies and product launches.
Chief Business Officer Andrew de Guttadauro
Andrew de Guttadauro holds the position of Chief Business Officer, bringing with him over three decades of expertise in the biopharma sector. Throughout his career, he has demonstrated exceptional skill in business development and commercialization within the industry.
Biopharma Business Development Experience
Andrew de Guttadauro has extensive experience in biopharma business development and commercialization. One of his notable roles includes managing the commercial aspects of Biogen Idec's radiopharmaceutical, Zevalin. He also excelled as Vice President of Business Development at Vical, where he oversaw collaborations with major pharmaceutical companies such as Novartis and Merck.
Accomplishments in Drug Licensing and Partnerships
Andrew de Guttadauro has been instrumental in securing significant business deals and partnerships. He led the out-licensing of Oncolytics' pelareorep to Adlai Nortye for the Chinese and select Asian markets in a deal valued at eighty-seven million dollars. Additionally, he secured financial backing from Pfizer for a phase two breast cancer study and from Roche for studies in breast cancer and gastrointestinal cancers.
Commercial Launch Successes
Throughout his career, Andrew de Guttadauro has been involved in the successful launches of several high-profile pharmaceutical products. His contributions were pivotal to the successful launches of Takeda's Prevacid and Amgen's Aranesp, as well as the relaunch of Amgen's Enbrel. These experiences highlight his proficiency in guiding products from development to market success.
Funding Initiatives and Support Secured
Andrew de Guttadauro has demonstrated a keen ability to secure funding and support for various research and development projects. Notably, while at Vical, he secured financial support from the U.S. Naval Medical Research Center for the development of an H1N1 vaccine. His ability to attract financial backing underscores his valuable expertise within the biopharma industry.